Transmedics Group Inc is a biotechnology company focused on revolutionizing the organ transplant process through innovative medical technologies
They have developed a unique organ preservation and transportation system that optimizes the viability of donor organs, specifically targeting hearts, lungs, and livers. By employing advanced perfusion technology, Transmedics aims to improve patient outcomes and increase the availability of transplantable organs, ultimately addressing the critical shortages faced in the transplant community. Their commitment to enhancing the transplant experience positions them as a leader in the field of organ transplantation.
NEW YORK, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQTMDX) for violations of the federal securities laws on behalf of investors who purchased or acquired TransMedics common stock between February 28, 2023 and January 10, 2025, inclusive (the “Class Period”).
RADNOR, PA - February 27, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against TransMedics Group, Inc. (“TransMedics”) (NASDAQTMDX) on behalf of those who purchased or otherwise acquired TransMedics securities between February 28, 2023, and January 10, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is April 15, 2025.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In TransMedics To Contact Him Directly To Discuss Their Options
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of FMC Corporation (NYSEFMC), TransMedics Group, Inc. NASDAQ:TMDXNASDAQTMDX)(NASDAQ: ALARNASDAQALAR, and Constellation Brands, Inc. (NYSE:STZNYSE). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons or entities who purchased or otherwise acquired TransMedics Group, Inc. (NASDAQTMDX) securities between February 28, 2023 and January 10, 2025. TransMedics describes itself as a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states.
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQTMDX) for violations of the federal securities laws on behalf of investors who purchased or acquired TransMedics common stock between February 28, 2023 and January 10, 2025, inclusive (the “Class Period”).
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against TransMedics Group, Inc. (“TransMedics” or “the Company”) (NASDAQTMDX) and certain of its officers.
RADNOR, PA - February 21, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against TransMedics Group, Inc. (“TransMedics”) (NASDAQTMDX) on behalf of those who purchased or otherwise acquired TransMedics securities between February 28, 2023, and January 10, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is April 15, 2025.
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against TransMedics Group, Inc. (“TransMedics”) (NASDAQTMDX) on behalf of those who purchased or otherwise acquired TransMedics securities between February 28, 2023, and January 10, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is April 15, 2025.
RADNOR, PA - February 19, 2025 (NEWMEDIAWIRE) - The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against TransMedics Group, Inc. (“TransMedics”) (NASDAQTMDX) on behalf of those who purchased or otherwise acquired TransMedics securities between February 28, 2023, and January 10, 2025, inclusive (the “Class Period”). The lead plaintiff deadline is April 15, 2025.
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of TransMedics Group, Inc. (NASDAQTMDX) publicly traded securities between February 28, 2023 and January 10, 2025, both dates inclusive (the “Class Period”), have until April 15, 2025 to seek appointment as lead plaintiff of the TransMedics class action lawsuit. Captioned Jewik v. TransMedics Group, Inc., No. 25-cv-10385 (D. Mass.), the TransMedics class action lawsuit charges TransMedics as well as certain of TransMedics’ top executives with violations of the Securities Exchange Act of 1934.
SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of all persons and entities who purchased or otherwise acquired TransMedics Group, Inc. (NASDAQTMDX) (“TransMedics” or the “Company”) securities between February 28, 2023 and January 10, 2025 (the “Class Period”), charging the Company and certain senior executives with violations of the federal securities laws (collectively, “Defendants”).
NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQTMDX) between February 28, 2023 and January 10, 2025, inclusive.
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In TransMedics To Contact Him Directly To Discuss Their Options
SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all persons or entities who purchased or otherwise acquired TransMedics Group, Inc. (NASDAQTMDX) securities between February 28, 2023 and January 10, 2025. TransMedics describes itself as a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states.
NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQTMDX) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired TransMedics securities between February 28, 2023 and January 10, 2025, both dates inclusive (the “Class Period”). Investors have until April 15, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the District of Massachusetts on behalf of those who acquired TransMedics Group, Inc. (“TransMedics” or the “Company”) (NASDAQTMDX) securities during the period from February 28, 2023, through January 10, 2025 (“the Class Period”). Investors have until April 15, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit.
